drugset
Drugs / Tiespectus
last change Apr 2026 re-read 3 minutes ago

Tiespectus

Developed for
choroidal neovascularization · wet macular degeneration
Investigated by
EyeBiotech Ltd.

Trials 2

today NCT07496567 · Ph 2/3 NCT07440225 · Ph 2/3
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT07496567 Apr 2026 → Jul 2028 expected choroidal neovascularization, wet macular degeneration EyeBiotech Ltd. Recruiting No outcome recorded
Phase 2/3 NCT07440225 Mar 2026 → Jun 2028 expected choroidal neovascularization, wet macular degeneration EyeBiotech Ltd. Recruiting No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2026-04-02 Merck Sharp & Dohme LLC MSD Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration msd.com ↗
2026-04-02 Merck Sharp & Dohme LLC Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration merck.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Tiespectus ClinicalTrials.gov intervention name — accepted as the source's own label NCT07440225 ↗
1

NCT07496567 ↗
Route Intravitreal “Administered by intravitreal (IVT) injection” NCT07440225 ↗